Bristol Myers to CEO Caforio: Good job on Celgene so far, but you'll have to work for your raise

Bristol Myers Squibb's top shareholders offered advice to the company as to how it should revise its executive compensation in light of the company's $74 billion merger with Celgene. As a result of those discussions, the value of CEO Giovanni Caforio's dipped slightly to $18.8 million, as both his short-term and long-term incentives were tied to a successful integration.